The AJMC® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.
April 12th 2024
Patients with radiographic axial spondyloarthritis (ax-SpA) and a high risk of radiographic progression had similar low progression on both secukinumab and an adalimumab biosimilar.
December 31st 2023
Switches to Adalimumab Biosimilars Yielded Similar Outcomes to the Reference Product in IBD
May 21st 2021After switching to 1 of 2 adalimumab biosimilars, patients with inflammatory bowel disease (IBD) experienced comparable clinical outcomes to the reference product after 6 months, according to a recent study.
Read More
Alvotech Heats Up Patent Dispute Conflict by Suing AbbVie Over Humira Biosimilar
May 11th 2021Under the lawsuit, Alvotech alleges that AbbVie is unlawfully taking advantage of patent laws and claims courts to prevent biosimilar competition rivaling its blockbuster drug, Humira, from entering the US market.
Read More
Dr. Ryan Haumschild Outlines Ways to Boost Physician Confidence in Biosimilars
December 1st 2020Ryan Haumschild, PharmD, director of pharmacy at Emory Healthcare in Atlanta, Georgia, discussed results to the survey he conducted on biosimilar utilization and planned initiatives about how to increase physician confidence in biosimilars.
Watch
Association Details Why BPCIA Should Stay Even If ACA Falls
May 27th 2020The Association of Accessible Medicines (AAM), which supports biosimilar development, argues that even if the Affordable Care Act (ACA) is overturned by the Supreme Court later this year, the Biologics Price Competition and Innovation Act (BPCIA) is severable and should survive.
Read More
Models Show Switch to Bevacizumab, Rituximab Biosimilars Yields Millions in Savings
May 25th 2020Cost savings are likely to occur should payers switch from originator bevacizumab or rituximab to their respective biosimilars, according to research from 2 studies presented at the Virtual 2020 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) meeting.
Read More
Pharmacies Adapt in the Wake of Challenges Created by COVID-19, Panel Says
May 15th 2020In light of the coronavirus disease 2019 (COVID-19) pandemic, pharmacies have implemented new strategies to ensure their patients continue to receive care, especially for those who have lost their insurance or have underlying conditions, speakers said this week during the Pharmacy Quality Alliance (PQA) 2020 Annual Meeting.
Read More
Consumers, Employers, and Prescription Drugs During COVID-19: A Q&A With Arxcel's Chris Robbins
May 12th 2020How will coronavirus disease 2019 (COVID-19) affect prescription drug trends? The American Journal of Managed Care® (AJMC®) put questions to Chris Robbins, chief executive officer of Arxcel Consulting LLC, to review these subjects and more in a wrapup discussion after the Academy of Managed Care Pharmacy virtual meeting.
Read More
Proposed Bevacizumab Biosimilar for mCRC Found Noninferior to Reference Drug
May 8th 2020A proposed bevacizumab biosimilar, BE1040V, was found to be noninferior to its reference product (Avastin) in terms of efficacy for the treatment of metastatic colorectal cancer (mCRC), according to a study published in Clinical Therapeutics.
Read More